Offering Enhanced onsite and off-site management
Brooks Automation is a leading provider of life science and semiconductor manufacturing automation solutions worldwide. It has recently acquired RURO Inc., an informatics software company based in Frederick, Maryland.
Subject to customary working capital and other adjustments, the total cash purchase price of the acquisition was $15 million. Cloud-based software solutions are provided by RURO to manage laboratory workflow and bio-sample data for a broad range of customers in biotech, healthcare, and pharmaceutical sectors. MD Anderson, Amgen, Exact Sciences, NIH are RURO’s typical customers. Brooks will offer enhanced onsite and off-site management of biological sample inventories as well as integration solutions to its customers for their increasingly distributed workflow.
Acquisition to be accretive to non-GAAP earnings
“I’m managing more than 50 million samples on behalf of customers; we have long been in a position to offer information management solutions to many of our customers. We have worked with RURO in recent years and found their solutions are very effective at resolving the challenges of integrating multi-laboratory workflows, managing distributed inventories, and providing information security in a single solution. We are in an ideal position to offer and implement these comprehensive software solutions with increased value for our customers,” said Steve Schwartz, President, and CEO of Brooks Automation.
Brooks Automation has aligned RURO management under the Brooks Life Sciences business in its Sample Management Operations. RURO generated approximately $5 million in revenue last year and expects the acquisition to be accretive to non-GAAP earnings within the first year.
Brooks Automation provides a full suite of reliable cold-chain sample management solutions across life sciences in areas such as drug development, clinical research, and advanced cell therapies by applying its automation and cryogenics expertise. It recently acquired GENEWIZ to expand its sample-based service offerings. It added global capability for gene sequencing and gene synthesis services through this strategic acquisition.